Physician profile
Daniel Harmuth
NPI 1346646114
$406.55
in general payments reported to CMS, 2019-2025
12 companies · $89.01 in 2025
The $89.01 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.06 · 2022: $56.84 · 2023: $75.25 · 2024: $112 · 2025: $89.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $276.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $107.84 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $62.81 | 2021-2022 | |
| Amgen INC. | $58.89 | 2023-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $34.91 | 2024 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $24.59 | 2022 | |
| Medtronic, INC. | $23.40 | 2021 | |
| Daiichi Sankyo INC. | $19.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.92 | 2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $16.80 | 2024 | Rexulti |
| Verona Pharma, INC. | $14.33 | 2025 | Ohtuvayre |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.77 | 2023 | Xifaxan |
| Lilly USA, LLC | $13.19 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Harmuth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.